Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.
- Resource Type
- Article
- Source
Clinical Infectious Diseases . Jun2018, Vol. 66 Issue 11, p1794-1797. 4p.- Subject
- *
LAMIVUDINE
*DRUG resistance in microorganisms
*HIV infections
*PILOT projects
*RANDOMIZED controlled trials
*HIGHLY active antiretroviral therapy
*TREATMENT effectiveness
*THERAPEUTICS - Language
- ISSN
- 1058-4838